Actively Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Led by Genentech, Inc. · Updated on 2026-05-04
250
Participants Needed
18
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
CONDITIONS
Official Title
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Life expectancy of at least 3 months according to investigator judgment
- Adequate blood counts and organ function
- Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that progressed after standard therapy, or if standard therapy is ineffective, intolerable, or inappropriate, or if clinical trial is standard care
- Measurable disease based on RECIST v1.1 criteria
- Availability of tumor specimen for certain cohorts
You will not qualify if you...
- Any anti-cancer therapy, investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks before starting treatment
- Active hepatitis B or C infection
- Active tuberculosis
- Positive test for HIV infection
- Received live, attenuated vaccine within 4 weeks before RO7566802 infusion
- Symptomatic, untreated, or actively progressing central nervous system metastases
- Active or history of autoimmune disease
- Prior allogeneic stem cell or organ transplant
- Uncontrolled tumor-related pain
- Significant cardiovascular disease
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
Yale Cancer Center
New Haven, Connecticut, United States, 06520
Actively Recruiting
3
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York, United States, 10029
Actively Recruiting
4
The Ohio State University
Columbus, Ohio, United States, 43221-3502
Actively Recruiting
5
Magee-Woman's Hospital
Harrisburg, Pennsylvania, United States, 17109
Actively Recruiting
6
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
7
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia, 2010
Actively Recruiting
8
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Actively Recruiting
9
British Columbia Cancer Agency - 600 10th Ave W
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
10
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1Z5
Actively Recruiting
11
National University Hospital
Singapore, Singapore, 119074
Actively Recruiting
12
National Cancer Centre
Singapore, Singapore, 168583
Actively Recruiting
13
Addenbrooke's Hospital
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
14
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW
Actively Recruiting
15
St Bartholomew's Hospital
London, United Kingdom, EC1A 7BE
Actively Recruiting
16
Sarah Cannon Research Institute
London, United Kingdom, W1G 6AD
Actively Recruiting
17
Churchill Hospital
Oxford, United Kingdom, OX3 7LJ
Actively Recruiting
18
The Royal Marsden hospital
Sutton, United Kingdom, SM2 5PT
Actively Recruiting
Research Team
R
Reference Study ID Number: GO44431 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here